CytomX Therapeutics (CTMX) Lifted to Buy at Goldman Sachs Group

Goldman Sachs Group upgraded shares of CytomX Therapeutics (NASDAQ:CTMX) from a neutral rating to a buy rating in a research report sent to investors on Thursday morning, The Fly reports.

CTMX has been the subject of a number of other research reports. BidaskClub lowered CytomX Therapeutics from a hold rating to a sell rating in a report on Wednesday, August 15th. ValuEngine lowered CytomX Therapeutics from a buy rating to a hold rating in a report on Monday, September 17th. HC Wainwright set a $32.00 price target on CytomX Therapeutics and gave the company a buy rating in a report on Wednesday, October 24th. Zacks Investment Research lowered CytomX Therapeutics from a hold rating to a sell rating in a report on Tuesday, October 9th. Finally, reiterated a hold rating on shares of CytomX Therapeutics in a report on Tuesday, November 6th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of Buy and an average target price of $32.47.

CTMX opened at $14.77 on Thursday. CytomX Therapeutics has a one year low of $12.51 and a one year high of $35.00.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Thursday, November 8th. The biotechnology company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.11). The business had revenue of $12.51 million for the quarter, compared to the consensus estimate of $16.42 million. CytomX Therapeutics had a negative net margin of 68.90% and a negative return on equity of 65.03%. On average, equities analysts predict that CytomX Therapeutics will post -1.78 earnings per share for the current year.

In other CytomX Therapeutics news, insider Sean A. Mccarthy sold 6,526 shares of the company’s stock in a transaction on Friday, November 2nd. The stock was sold at an average price of $15.00, for a total transaction of $97,890.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Debanjan Ray sold 3,000 shares of the company’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $18.46, for a total value of $55,380.00. Following the sale, the chief financial officer now owns 8,928 shares of the company’s stock, valued at approximately $164,810.88. The disclosure for this sale can be found here. Insiders sold 15,526 shares of company stock valued at $243,270 in the last quarter. 8.50% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the business. State of Wisconsin Investment Board lifted its holdings in CytomX Therapeutics by 87.1% during the second quarter. State of Wisconsin Investment Board now owns 39,300 shares of the biotechnology company’s stock worth $898,000 after buying an additional 18,300 shares during the period. Vident Investment Advisory LLC lifted its holdings in CytomX Therapeutics by 26.2% during the second quarter. Vident Investment Advisory LLC now owns 99,904 shares of the biotechnology company’s stock worth $2,284,000 after buying an additional 20,761 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in CytomX Therapeutics by 18.9% during the second quarter. Schwab Charles Investment Management Inc. now owns 235,926 shares of the biotechnology company’s stock worth $5,394,000 after buying an additional 37,560 shares during the period. MetLife Investment Advisors LLC lifted its holdings in CytomX Therapeutics by 35.9% during the second quarter. MetLife Investment Advisors LLC now owns 18,290 shares of the biotechnology company’s stock worth $418,000 after buying an additional 4,831 shares during the period. Finally, FMR LLC lifted its holdings in CytomX Therapeutics by 0.9% during the second quarter. FMR LLC now owns 5,843,626 shares of the biotechnology company’s stock worth $133,586,000 after buying an additional 51,953 shares during the period. Institutional investors own 83.79% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Recommended Story: Inflation

The Fly

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit